Tempus AI, Inc.
Category: AI in Healthcare
Tempus is a technology company that is building the world's largest library of molecular and clinical data and an operating system to make that data accessible and useful for physicians, researchers, and life sciences companies. Tempus AI, Inc. was founded in 2015. The company is led by Eric Lefkofsky. Based in Chicago, Illinois, USA. Team size: 3000+. Total funding raised: $1.35 billion. Latest round: IPO, $410.0M, 2024-06. Key investors include Baillie Gifford, Franklin Templeton, Google, T. Rowe Price, SoftBank.
- Founded
- 2015
- Headquarters
- Chicago, Illinois, USA
- Team size
- 3000+
- Total funding
- $1.35 billion
Value proposition
To provide AI-driven, data-backed insights to personalize patient care and accelerate the discovery, development, and delivery of optimal therapeutics.
Products and solutions
Genomic Sequencing Services (Tempus xT, xF, xR, xG, xE), Tempus ONE (AI-enabled voice and text platform), Tempus NEXT (AI-enabled care pathway intelligence platform), Data and Services (Insights, Trials), Algos (algorithmic tests), Hub (platform for ordering and managing tests), Lens (data analysis platform)
Unique value
Tempus's core innovation lies in its creation of a massive, proprietary library of multimodal data (clinical, molecular, and imaging data) combined with an operating system that uses AI to generate insights for both clinical care and research. This creates a powerful flywheel effect where more data leads to better insights, which in turn attracts more partners and customers, further expanding the dataset.
Target customer
Oncologists, pathologists, radiologists, and other physicians; researchers at academic medical centers and pharmaceutical companies.
Industries served
Oncology, Neuropsychiatry, Cardiology, Radiology, Infectious Diseases
Technology advantage
The primary technological advantage is the company's large-scale data and sophisticated AI platform. The business advantage comes from its established relationships with a large network of hospitals and cancer centers, which provides a continuous flow of data and a ready market for its products and services. The recent acquisition of Ambry Genetics further strengthens their position in hereditary cancer testing.
How they differentiate
Tempus AI differentiates itself through its vast and proprietary library of clinical and molecular data, which it leverages with AI to provide insights for precision medicine. The company has a dual business model, offering both genomic sequencing diagnostics and data licensing to pharmaceutical companies. This creates a powerful network effect, where more data enhances its AI models, attracting more users and data, further strengthening its competitive moat.
Main competitors
Foundation Medicine, Flatiron Health, Caris Life Sciences
Key partnerships
AstraZeneca, GSK, Bristol Myers Squibb, Merck, NYU Langone Health, Northwestern Medicine, Institute for Follicular Lymphoma Innovation, Paige (acquired by Tempus), Ambry Genetics (acquired by Tempus)
Notable customers
AstraZeneca, GSK, Bristol Myers Squibb, Merck, Johnson & Johnson, NYU Langone Health, Northwestern Medicine
Major milestones
Completed its Initial Public Offering (IPO) in June 2024., Received FDA approval for its companion diagnostic test, xT CDx., Acquired Ambry Genetics in 2024., Acquired Paige for $81.25M in August 2025, adding 7M digitized pathology slides and AI foundation model., Launched Paige Predict AI-powered digital pathology suite., Full year 2025 revenue reached $1.3B, up 83.4% YoY., Achieved positive Adjusted EBITDA in Q4 2025., Expanded platform to cardiology, neuropsychiatry, and infectious diseases.
Growth metrics
Tempus AI reported full year 2025 revenue of $1.3 billion, up 83.4% year-over-year. Diagnostics revenue was $955.4M, Data & Applications revenue was $316.4M. Ended 2025 with $759.7M cash and $1.1B+ total remaining contract value. 2026 guidance: ~$1.59B revenue and ~$65M Adjusted EBITDA.
Market positioning
Tempus AI is a leader in the precision medicine market, with a primary focus on oncology. The company is well-positioned with its comprehensive platform that integrates genomic data with clinical data to help physicians make data-driven decisions. It is expanding its reach into other areas, including cardiology, neuropsychiatry, and radiology, to become a broader diagnostics and data company.
Geographic focus
Tempus AI is headquartered in Chicago, USA, and its primary market is North America. However, the company has a global reach through its partnerships with pharmaceutical companies and research institutions worldwide.
Patents and IP
Tempus AI, Inc. and its subsidiary Tempus Labs, Inc. hold multiple patents for their technology. These patents cover methods and systems for predicting cardiac events, analyzing de-identified patient data to create dynamic user interfaces for predicting patient responses to treatments, and systems for matching patients to clinical trials. However, the company is currently in a patent infringement lawsuit with Guardant Health.
About Eric Lefkofsky
Eric Lefkofsky is a co-founder of several companies, including Tempus, Groupon, Echo Global Logistics, InnerWorkings, and Mediaocean. He is also a co-managing partner at Lightbank, a venture capital firm.
Official website: https://www.tempus.com/